



Early detection can make a difference


New Benefit! Live January 2025



The Galleri[®] multi-cancer early detection test

We're committed to our associates' health. That's why we're excited to offer you a new health benefit -- the Galleri multi-cancer early detection test. This groundbreaking test screens for a signal shared by more than 50 types of cancer with just a simple blood draw.¹

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. The Galleri test should be used in addition to healthcare provider recommended screening tests. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer.



cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment. Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of "No Cancer Signal Detected" does not rule out cancer. A test result of "Cancer Signal Detected" requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer. If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. **Rx only**.

Laboratory / Test Information: GRAIL's clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. GRAIL's clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.

1. Klein EA, et al. Ann Oncol. 2021;32(9): 1167–1177. doi: 10.1016/j.annonc.2021.05.806.

Look for more information on the benefit and eligibility coming soon from your benefits team.



Scan to watch Roger's patient story.